Bavarian Nordic
191.35
DKK
-0.88 %
BAVA
NASDAQ Copenhagen
Biotechnology & Pharmaceuticals
Health Care
51 following
-0.88%
-4.37%
-11.86%
-28.52%
+7.05%
+7.83%
+25.19%
-37.45%
+49.5%
+34.15%
www.bavarian-nordic.com/investor.aspx
Bavarian Nordic is a biochemistry company. Today, the company specializes in the development, manufacture, and distribution of vaccines against infectious diseases in connection with cancer treatment. In addition, vaccines against other serious diseases such as Ebola and cervical cancer are also being developed. The largest operations are located in Europe and in the U.S. Bavarian Nordic was founded in 1994 and is headquartered in Kvistgaard, Denmark.
Revenue
7.06B
EBIT %
21.28 %
P/E
9.97
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
NASDAQ Copenhagen
BAVA
Daily low / high price
189.05 / 192.9
DKK
Market cap
15.08B DKK
Turnover
16.22M DKK
Volume
85K
Latest videos
Financial calendar
Annual report
05.03.2025
General meeting
09.04.2025
Interim report
09.05.2025
Interim report
22.08.2025
Interim report
14.11.2025
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
ATP Group | 10.1 % | 10.1 % |
Invesco | 5.0 % | 5.0 % |
ShowingAll content types
Bavarian Nordic Announces Interim Results for the First Nine Months of 2024
Bavarian Nordic offentliggør delårsregnskab for de første ni måneder af 2024
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools